Skip to main content
. Author manuscript; available in PMC: 2019 Oct 28.
Published in final edited form as: J Control Release. 2018 Sep 6;288:111–125. doi: 10.1016/j.jconrel.2018.09.003

Figure 12.

Figure 12.

PIP 640 enhances the transport of a positively-charged therapeutic peptides in vitro and in vivo. A) Changes in TEER relative to initial values 60 min after apical application of 1 mM PIP 640 to Caco2 cell monolayers. B) Cumulative apical to basal transport across polarized Caco-2 cell monolayers in vitro of exenatide and salmon calcitonin after 60 min. Data are means ± SEM of 3 independent experiments, with n=6 (***P < 0.001, ****P < 0.0001). Portal vein concentration-time profiles of C) Exenatide and D) salmon calcitonin following in vivo ILI with or without 20 mM PIP 640. Data are means ± SEM of 3 independent experiments; n= 3. One-way ANOVA indicated a significant difference between the data sets (**p value< 0.01).

HHS Vulnerability Disclosure